KAIST’s breakthrough in colon cancer uses BENEIN to target MYB, HDAC2, FOXA2—offering a potential cure without chemo. A new era in South Korea cancer treatment.
KAIST’s breakthrough in colon cancer uses BENEIN to target MYB, HDAC2, FOXA2—offering a potential cure without chemo. A new era in South Korea cancer treatment.